A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

NCT01676831

Cutaneous T Cell Lymphoma

COMPLETED PHASE1/PHASE2

Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

NCT01808950

Nodular Basal Cell Carcinoma

TERMINATED PHASE1/PHASE2

HPV Vaccine, Imiquimod, and Metformin Combination Trial

NCT06686043

Cervical Carcinoma Vaginal Carcinoma Vulvar Carcinoma +1 more

RECRUITING PHASE2

IBRX-042 In Participants With HPV-Associated Tumors

NCT05976828

HPV-Related Carcinoma

ACTIVE_NOT_RECRUITING PHASE1

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

NCT02239731

Rash Due to Epidermal Growth Factor Receptor Inhibitors

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NY-ESO-1 is a protein that is often made by some types of tumor cells, but only made by a few types of normal cells. Because it is primarily made by cancer cells, the NY-ESO-1 protein is a promising target against which to stimulate an immune response that may destroy cancer cells. CDX-1401 is a cancer vaccine that is specially designed to create this type of immune response. To enhance the immune response, CDX-1401 will be given with 1 or 2 immune stimulants called Resiquimod and poly-ICLC (Hiltonol).

This clinical trial includes Phase 1 and Phase 2 segments. During the Phase 1 segment, six groups of 6 to 24 patients will be treated with different dose levels of CDX-1401 in combination with either one or both of the immune stimulants (Resiquimod and/or poly-ICLC). This phase of the study will test the safety profile of the vaccine treatment, and will assess which dose to test in future studies. During the Phase 2 segment, 14 patients whose cancer tested positive for the NY-ESO-1 protein in laboratory testing, will receive the study treatment to determine if it has an effect on their cancer. All patients enrolled in either part of the study may continue to receive study treatment until their disease has progressed or until it is necessary to stop the treatment for safety or other reasons. In addition, all patients will be "followed" for 24 months after enrollment in order to collect survival information.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CDX-1401 in combination with Resiquimod and/or Poly-ICLC

CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.

Intervention Type BIOLOGICAL

CDX-1401

Intervention Type BIOLOGICAL

Resiquimod

Intervention Type BIOLOGICAL

poly-ICLC

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Among other criteria, patients must meet all of the following conditions to be eligible to be in the study:

1. 18 years of age or older.
2. Have a cancer type that is known to express NY-ESO-1, including (but not limited to) cancer of the bladder, breast, ovary, non-small cell lung cancer, myeloma, sarcoma or melanoma.
3. Have cancer that has progressed after any therapies with curative potential or approved salvage therapies (if such therapies exist).
4. Have evaluable or measurable tumors.
5. Have adequate blood, bone marrow, liver and kidney function as determined by laboratory tests.
6. Have a sample of tumor tissue available for NY-ESO-1 testing at a central laboratory.
7. If of childbearing potential (male or female), agree to practice an effective form of contraception during study treatment.

Exclusion Criteria

Among other criteria, patients who meet any of the following conditions are NOT eligible to be in the study:

1. Are receiving treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (inhaled or topically applied steroids are permitted).
2. Has a known infection with HIV, HBV or HCV, or any other active infection requiring systemic antibiotic treatment.
3. Has active central nervous system tumors.
4. Any underlying medical condition that in the Principal Investigator's opinion will make the administration of study drug hazardous or otherwise interfere with the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No